Guardant Health, Inc. Stock price

Equities

GH

US40131M1099

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-02-27 pm EST 5-day change 1st Jan Change
19.53 USD -3.03% Intraday chart for Guardant Health, Inc. -14.45% -27.80%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
limited-time offer
Enjoy this offer
* See conditions on site
Sales 2024 * 664M Sales 2025 * 803M Capitalization 2.45B
Net income 2024 * -401M Net income 2025 * -366M EV / Sales 2024 * 4.13 x
Net Debt 2024 * 292M Net Debt 2025 * 451M EV / Sales 2025 * 3.62 x
P/E ratio 2024 *
-6 x
P/E ratio 2025 *
-6.67 x
Employees 1,774
Yield 2024 *
-
Yield 2025 *
-
Free-Float 95.47%
More Fundamentals * Assessed data
Dynamic Chart
1 day-3.03%
1 week-14.45%
Current month-10.94%
1 month-18.66%
3 months-19.96%
6 months-48.90%
Current year-27.80%
More quotes
1 week
19.08
Extreme 19.08
22.81
1 month
19.08
Extreme 19.08
24.02
Current year
19.08
Extreme 19.08
27.61
1 year
19.08
Extreme 19.08
41.06
3 years
19.08
Extreme 19.08
169.43
5 years
19.08
Extreme 19.08
181.07
10 years
19.08
Extreme 19.08
181.07
More quotes
Managers TitleAgeSince
Founder 48 11-12-31
Founder 44 11-12-31
Chief Executive Officer 45 12-12-31
Members of the board TitleAgeSince
Director/Board Member 62 16-11-30
Director/Board Member 65 21-10-14
Director/Board Member 49 20-05-31
More insiders
Date Price Change Volume
24-02-27 19.53 -3.03% 3,196,931
24-02-26 20.14 +3.71% 3,701,038
24-02-23 19.42 -12.80% 5,346,057
24-02-22 22.27 -1.72% 1,746,495
24-02-21 22.66 -0.74% 1,391,574

Delayed Quote Nasdaq, February 27, 2024 at 04:00 pm EST

More quotes
Guardant Health, Inc. is a precision oncology company. The Company is focused on helping conquer cancer globally through the use of its proprietary tests, vast data sets and advanced analytics. The Company has developed its Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced-stage cancer. It also has developed Guardant360 TissueNext tissue test for advanced-stage cancer, Guardant Reveal blood test to detect residual and recurring disease in early-stage cancer patients, and Guardant360 Response blood test to predict patient response to immunotherapy or targeted therapy eight weeks earlier than current standard-of-care imaging. The Company's GuardantINFORM platform is used to help biopharmaceutical companies accelerate precision oncology drug development through the use of this in-silico research platform to unlock further insights into tumor evolution and treatment resistance across various biomarker-driven cancers.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
20.14 USD
Average target price
41.5 USD
Spread / Average Target
+106.06%
Consensus
  1. Stock
  2. Equities
  3. Stock Guardant Health, Inc. - Nasdaq
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW